NCT02439749已完成不适用
Global Clinical Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension in the Absence of Antihypertensive Medications (SPYRAL PIVOTAL - SPYRAL HTN-OFF MED)
Medtronic Vascular91 个研究点 分布在 9 个国家目标入组 366 人开始时间: 2015年6月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 366
- 试验地点
- 91
- 主要终点
- Number of Participants With Major Adverse Events (MAE) Defined as a Composite of Events.
研究概览
简要总结
The purpose of this study is to test the hypothesis that renal denervation decreases blood pressure and is safe when studied in the absence of antihypertensive medications.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Individual has office systolic blood pressure (SBP) ≥ 150 mmHg and <180 mmHg and a diastolic blood pressure (DBP) ≥ 90 mmHg after being off medications.
- •Individual has 24-hour Ambulatory Blood Pressure Monitoring (ABPM) average SBP ≥ 140 mmHg and < 170 mmHg.
- •Individual is willing to discontinue current antihypertensive medications.
排除标准
- •Individual lacks appropriate renal artery anatomy.
- •Individual has estimated glomerular filtration rate (eGFR) of <
- •Individual has type 1 diabetes mellitus or poorly-controlled type 2 diabetes mellitus.
- •Individual has one or more episodes of orthostatic hypotension.
- •Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea.
- •Individual has primary pulmonary hypertension.
- •Individual is pregnant, nursing or planning to become pregnant.
- •Individual has frequent intermittent or chronic pain that results in treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) for two or more days per week over the month prior to enrollment.
- •Individual has stable or unstable angina within 3 months of enrollment, myocardial infarction within 3 months of enrollment; heart failure, cerebrovascular accident or transient ischemic attack, or atrial fibrillation at any time.
- •Individual works night shifts.
结局指标
主要结局
Number of Participants With Major Adverse Events (MAE) Defined as a Composite of Events.
时间窗: From baseline to 1 month post-procedure (6 months for new renal artery stenosis)
All-cause mortality End-stage Renal Disease (ESRD) Significant embolic event resulting in end-organ damage Renal artery perforation requiring intervention Renal artery dissection requiring intervention Vascular complications Hospitalization for hypertensive crisis not related to confirmed non-adherence with medications or the protocol New renal artery stenosis \>70% (6 months for new renal artery stenosis)
Baseline Adjusted Change (Using Analysis of Covariance) in Systolic Blood Pressure as Measured by 24-hour Ambulatory Blood Pressure Monitoring
时间窗: From baseline to 3 months post-procedure
The outcome measure is the change in ambulatory systolic blood pressure from baseline to 3-month. The unadjusted treatment difference between renal denervation and sham control groups is -3.9 mmHg. The baseline adjusted treatment difference is -3.9 mmHg.
次要结局
- New Stroke(From baseline to 3 months post randomization)
- Number of Participants With Renal Artery Re-intervention(From baseline to 36 months post randomization)
- Number of Participants With Major Bleeding According to TIMI Definition(From baseline to 36 months post randomization)
- Number of Participants With Increase in Serum Creatinine(From baseline to 1 month post-procedure)
- Number of Participants With Hospitalization for Hypertensive Crisis With Medications or the Protocol(From baseline to 1 month post-procedure)
- Change in Office Systolic Blood Pressure(From baseline to 36 months post procedure)
- Change in Office Diastolic Blood Pressure(From baseline to 36 months post-procedure)
- Number of Participants Achieving Target Office Systolic Blood Pressure(From baseline to 3 months post procedure)
- Baseline Adjusted Change (Using Analysis of Covariance) in Office Systolic Blood Pressure(From baseline to 3 months post-procedure)
- Number of Participants With All-cause Mortality(From baseline to 36 months post-randomization)
- Number of Participants With ≥40% Decline in eGFR(From baseline to 36 months post randomization)
- Number of Participants With End-Stage Renal Disease (ESRD)(From baseline to 36 months post randomization)
- Number of Participants With New Myocardial Infarction(From baseline to 36 months post randomization)
- Increase in Serum Creatinine(From baseline to 3 months post randomization)
- Number of Participants With Hospitalization for Hypertensive Crisis(From baseline to 36 months post randomization)
- Change in Diastolic Blood Pressure as Measured by 24-hour ABPM(From baseline to 36 months post-procedure)
- Number of Participants With New Renal Artery Stenosis > 70%(From baseline to 36 months post randomization)
- Change in Systolic Blood Pressure as Measured by 24-hour ABPM(From baseline to 36 month post-procedure)
- Number of Participants With Incidence of Achieving Target Office Systolic Blood Pressure (SBP <140) mmHg)(From baseline to 36 months post-procedure)
- Number of Participants With New Stroke(From baseline to 36 months post randomization)
- Number of Participants With an Increase in Serum Creatinine(From baseline to 36 months post randomization)
- Number of Participants With Significant Embolic Event Resulting in End-organ Damage(From baseline to 1 month post-procedure)
- Number of Participants With Renal Artery Perforation Requiring Intervention(From baseline to 1 month post-procedure)
- Renal Artery Dissection(From baseline to 1 month post-procedure)
- Number of Participants With Vascular Complications(From baseline to 1 month post-procedure)
- Number of Participants With End-stage Renal Disease(From baseline to 1 month post-procedure)
- Number of Participants With Decline in eGFR(From baseline to 1 month post-procedure)
- Myocardial Infarction(From baseline to 1 month post-procedure)
研究者
研究点 (91)
Loading locations...
相似试验
已完成
不适用
SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation SystemVascular DiseasesCardiovascular DiseasesHypertensionNCT02439775Medtronic Vascular337
已完成
不适用
Renal Denervation in Patients With Resistant Hypertension and Obstructive Sleep ApneaObstructive Sleep ApneaHypertensionNCT01366625National Institute of Cardiology, Warsaw, Poland60
终止
4 期
Renal Denervation for Resistant HypertensionHypertensionNCT01865240Baker Heart and Diabetes Institute5
撤回
不适用
Renal Denervation for Uncontrolled HypertensionHypertensionNCT02016573Baker Heart and Diabetes Institute
招募中
不适用
Effect of Renal Denervation on Bood Pressure in Patients on HemodialysisTreatment Resistant HypertensionChronic HemodialysisNCT06556407University of Erlangen-Nürnberg Medical School12